Panel Discussion – Arthramid® Vet and other non-biologic joint medications

Learn about Arthramid® Vet from a panel of internationally renowned equine practitioners, sports medicine specialists & surgeons.

No account yet? Register


Veterinary Professional Development (VetPD) will convene a panel discussion on new intra-articular non-biologic joint medications and therapies including 2.5% polyacrylamide hydrogel, Arthramid® Vet on June 8, 2021. The 3 hour panel discussion will begin at 2:00 p.m. eastern time and will be recorded.

Learn about Arthramid® Vet from a panel of internationally renowned equine practitioners, sports medicine specialists & surgeons. The panel will discuss results from recently published studies along with clinical experience in managing osteo-arthritis in horses with polyacrylamide hydrogels including Arthramid® Vet. Panelists will include Florent David DVM, MS, Dipl. ACVS, Dipl. ECVS, Dipl. ACVSMR, ECVDI European & American Specialist in Equine Surgery; European Specialist in Diagnostic Imaging and American Specialist in Equine Sports Medicine/Rehabilitation Doha, Qatar; Scott McClure DVM, PhD, Dipl. ACVS, Dipl. ACVSMR American Specialist in Equine Surgery; American Specialist in Equine Sports Medicine. United States; Ben Ahern BVSc (Hons I) PhD MACVSc Dipl. ACVS Dip. ACVSMR, Section Head, Equine Specialist Hospital. Australia. Heidi Reesink VMD, PhD, DACVS-LA will serve as the moderator.

In November 2020, ConturaVet, manufacturer of Arthramid® Vet launched the product in the United States. Arthramid® Vet 2.5% polyacrylamide hydrogel is labeled for intra-articular  administration for the management of all stages of OA & DJD in horses in the USA.

Arthramid® Vet hydrogel products are developed and produced in our state-of-the-art FDA-approved GMP manufacturing facility in Denmark. Knowing how important quality of manufacturing is to veterinarians, this makes Arthramid® Vet the safe choice for your patients.

Arthramid® Vet is produced by a patented technology called In-line Cross-Linking Technology, which forces water molecules between the cross-linked polymers of polyacrylamide. This gives the hydrogel a unique molecular stability and the ability to retain its viscoelastic properties. It is non-toxic, neuro-innocuous and maintains its viscoelasticity over time.

Arthramid® Vet’s 2.5% PAAG is hydrophilic with lightly bound water molecules that can interchange with water molecules of surrounding synovial tissues. After administration, branching of the polyacrylamide chains takes place, and a three-dimensional matrix of cross-linked polyacrylamide is formed. The Arthramid® Vet matrix formed is less rigid than other PAAG scaffolds. Unique to Arthramid® Vet, the scaffold maintains uniform porosity allowing an ideal level of tissue integration and vessel ingrowth into the hydrogel matrix. This provides more stability for tissue ingrowth whereby creating a permanent scaffold that is integrated into the synovial tissue.

Arthramid® Vet contains no impurities, does not become encapsulated, has the most compatible pH range of all PAAG’s and is permanently stable.

Attendance is $65 for veterinarians. ConturaVet will reimburse current Arthramid® Vet customers their attendance fee to this meeting. Send your receipt to:

Visit to learn more.

For more information about Arthramid® Vet, please contact Nicola Woods at ConturaVet Phone: +44 (0) 845 862 3292


Written by:

Product and information releases by various organizations and companies.

Related Articles

Stay on top of the most recent Horse Health news with

FREE weekly newsletters from

Sponsored Content

Weekly Poll

sponsored by:

Has your veterinarian used SAA testing for your horse(s)?
92 votes · 92 answers

Readers’ Most Popular

Sign In

Don’t have an account? Register for a FREE account here.

Need to update your account?

You need to be logged in to fill out this form

Create a free account with!